JK Biostatistics
Industry / private company
Location:
Stockholm,
Sweden (SE)
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial (2020)
Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, et al.
Journal article
Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis (2016)
Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson A, Knittel T, et al.
Journal article